(Q28200571)

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Prophylactic aspirin and risk of peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Prevention of chronic NSAID induced upper gastrointestinal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Effect of ibuprofen on cardioprotective effect of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0610

7 January 2021